# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
CASI Pharmaceuticals (NASDAQ:CASI) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate o...
On April 8, 2024, CASI Pharmaceuticals, announced that, with respect to the Company’s previously announced dispute with Juventa...
On April 8, 2024, CASI Pharmaceuticals, Inc., a Cayman Islands incorporated company (“CASI” or the “Company”) announced that, ...
CASI Pharmaceuticals (NASDAQ:CASI) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate o...
CASI Pharmaceuticals (NASDAQ:CASI) reported quarterly losses of $(2.02) per share which missed the analyst consensus estimate o...
CASI Pharmaceuticals and BioInvent share promising results for BI-1206 in treating relapsed/refractory indolent Non-Hodgkin'...